• Regulatory

Guest blog: The Unified Patent Court (UPC) – now a real prospect

Tim Powell, Partner at Powell Gilbert LLP and member of the BIA’s Intellectual Property Advisory Committee (IPAC), talks about the Unified Patent Court becoming a real prospect in 2022.

CEO Update | 15 November 2021

Thank you to everyone who joined us at the Babraham Research Campus in Cambridge last week. It was great to meet BIA members, local start-ups and academics to talk about collaboration. We raised the question of whether more or better collaborations are needed, and ultimately found that success lies in finding a common goal and sharing the benefits of your product.

AAV reference material to be produced at the Cell and Gene Therapy Catapult Braintree in collaboration with the National Institute for Biological Standards and Control

London, UK, 16th September 2021 – A 6-month collaborative project was announced today that will help to accelerate the introduction of regulated advanced gene therapies that use Adenovirus-associated vectors (AAVs).

Boyds opens US office

Leading pharmaceutical and biotech product development consultancy Boyds has announced the opening of its US office in the Philadelphia area and welcomes Katy Rudnick who is appointed Vice President and Head of US Regulatory Affairs to head up the newly established US company.

Fieldfisher Life Sciences group publishes white paper - The future of medicine: Cell and gene therapy

Leading European law firm Fieldfisher has launched white paper titled 'the future of medicine: Cell and gene therapy', an insight into the regulatory landscape for advanced therapy medicinal products and the potential of cell and gene therapy in the UK and other key hotspots in Europe post-Covid.

Experienced regulatory professionals join the Boyds team

Leading pharmaceutical and biotech product development consultancy Boyds has added to its regulatory team with the appointments of Shalini Gupta and Sarah Stevenson in response to recent growth and the continued increase in demand for its dedicated regulatory services.

Boyds launches recruitment drive following surge in growth

Turnover at leading pharmaceutical and biotech product development consultancy Boyds has surged by a record-breaking 25 percent as demand for its specialist services continues to grow.

Advanced Therapy Treatment Centre network awarded £9.5m further investment

The UK Government grant will support new and existing projects until March 2022. Funding will ensure that the positive impact of the ATTC network continues; further optimising the UK ecosystem for routine adoption of advanced therapies.

Autolus Therapeutics to further expand operations at the CGT Catapult manufacturing centre to enable commercial manufacture of CAR-T cell therapies

Autolus and CGT Catapult are collaborating to achieve approval for commercial manufacture of CAR-T cell therapies from the CGT Catapult manufacturing centre. The collaboration will enable the UK company to expand further and contribute to the global competitiveness of the UK cell and gene therapy industry.

Press Release: Over £100m cash boost to manufacture millions of doses of COVID-19 vaccine

- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment - Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills - New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics